Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17651682 | 0.71 | RAB9A (0.50) | CYP2D6ALDH1A1USP2MAPTMEN1 | |
| SCHEMBL11370824 | 0.64 | CHRNB4 (0.65) | CYP2D6SIGMAR1HRH3 | |
| SCHEMBL14417569 | 0.64 | HRH3 (0.51) | ATMCYP2D6SIGMAR1KCNH2ALDH1A1 | |
| SCHEMBL23886286 | 0.64 | CYP2D6 (0.53) | CYP2D6SIGMAR1KCNH2ALDH1A1IDO1 | |
| SCHEMBL23459354 | 0.64 | ATM (0.44) | ATMCYP2D6ALDH1A1USP2MEN1 | |
| SCHEMBL11379176 | 0.62 | SIGMAR1 (0.51) | CYP2D6SIGMAR1KCNH2ALDH1A1USP2 | |
| SCHEMBL7114249 | 0.62 | CYP2D6 (0.50) | CYP2D6SIGMAR1KCNH2ALDH1A1GAA | |
| SCHEMBL21015413 | 0.62 | IDO1 (0.47) | CYP2D6SIGMAR1KCNH2ALDH1A1GAA | |
| SCHEMBL7446651 | 0.62 | CYP2D6 (0.50) | CYP2D6SIGMAR1HRH3MEN1KMT2A | |
| SCHEMBL23091740 | 0.61 | CYP2D6 (0.45) | CYP2D6ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017441-B2 | Direct anti-markovnikov addition of acids to alkenes | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2018-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10017441-B2 | Direct anti-markovnikov addition of acids to alkenes | HAO2, DUOX2, PDK2 | ATM 677/4885CYP2D6 165/4885SIGMAR1 2222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.